HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Stalevo

Levodopa, carbidopa & entacapone (Catechols), intended as improved therapy for Parkinson Disease

Networked: 29 relevant articles (4 outcomes, 11 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Levin, O S: 4 articles (01/2013 - 01/2006)
2.	Hauser, Robert A: 4 articles (07/2009 - 01/2004)
3.	Klivényi, Péter: 2 articles (05/2009 - 01/2008)
4.	Vécsei, László: 2 articles (05/2009 - 01/2008)
5.	Babina, L A: 2 articles (11/2008 - 01/2007)
6.	Batysheva, T T: 2 articles (11/2008 - 01/2007)
7.	Khozova, A A: 2 articles (11/2008 - 01/2007)
8.	Kostenko, E V: 2 articles (11/2008 - 01/2007)
9.	Malykhina, E A: 2 articles (11/2008 - 01/2007)
10.	Minaeva, N G: 2 articles (11/2008 - 01/2007)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 01/01/2008 - "Despite the increase in cost, the use of stalevo in the treatment of Parkinson's disease with motor fluctuations is cost-effective in long-term (already after two years) management of patients." 01/01/2008 - "An open randomized study of pharmacoeconomic efficacy of stalevo in patients with Parkinson's disease with motor fluctuations was conducted. " 01/01/2008 - "[The clinical-pharmacoeconomic study of efficacy of stalevo in the treatment of Parkinson's disease with motor fluctuations]." 01/01/2014 - "To assess the efficacy and tolerability of the three component drug stalevo in the treatment of patients with Parkinson's disease (PD). " 01/01/2014 - "[The use of stalevo in the treatment of patients with Parkinson's disease]."
2.	Hypotension (Low Blood Pressure) 01/01/2006 - "The authors studied 15 patients with PD, aged 55.6+/-8.7 years, illness duration 7.7+/-3.1 years, who received stalevo during 6 weeks and revealed that stalevo reduced significantly the intensity of main PD symptoms, especially hypotension and rigidity as well as motor fluctuations, and improved general movement and daily activity of patients thus ameliorating their quality of life. "
3.	Dyskinesias (Dyskinesia) 01/01/2019 - "A subset analysis was used to validate an online dyskinesia-risk calculator developed from the results of the Stalevo Reduction in Dyskinesia Evaluation PD trial. " 01/01/2019 - "Replication of the Stalevo Reduction in Dyskinesia Evaluation PD calculator was reasonable with the area under the curve for dyskinesia risk score as a predictor of dyskinesia being 0.68 (95% confidence interval, 0.55-0.81). " 02/01/2011 - "Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint." 01/01/2009 - "Switching from conventional levodopa to stalevo is efficacy and safety and can significantly improve QOL PD patients with fluctuations and dyskinesias." 01/01/2013 - "[Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study]."
4.	Myocardial Infarction 04/01/2013 - "The controlled trial Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) reported an unexpected increase in acute myocardial infarction (AMI) with entacapone use in patients with Parkinson's disease (PD). "
5.	Lymphocytic Colitis 08/01/2008 - "[Stalevo-associated lymphocytic colitis]."

Related Drugs and Biologics

1.	entacapone (Comtan)
2.	Levodopa (L Dopa)
3.	Carbidopa (Lodosyn)
4.	levodopa drug combination carbidopa (Nakom)
5.	Catechol O-Methyltransferase Inhibitors
6.	Dopamine Receptors (Dopamine Receptor)
7.	Dopa Decarboxylase
8.	Tablets
9.	Dihydroxyphenylalanine (Dopa)
10.	Catechol O-Methyltransferase (Methyltransferase, Catechol)

Related Therapies and Procedures

1.	Therapeutics